XML 47 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Equity and Other Investments and Fair Value Measurements - Equity Investment in Armata (Details) - Armata
$ / shares in Units, $ in Millions
3 Months Ended
Mar. 04, 2024
USD ($)
Jul. 10, 2023
USD ($)
Jan. 10, 2023
USD ($)
Feb. 09, 2022
USD ($)
$ / shares
shares
Mar. 31, 2024
USD ($)
Director
Tranche
Mar. 31, 2023
USD ($)
Dec. 31, 2021
USD ($)
shares
Mar. 31, 2021
USD ($)
shares
Mar. 31, 2020
USD ($)
shares
Jan. 01, 2024
$ / shares
Dec. 31, 2023
USD ($)
Equity Investment                      
Number of tranches | Tranche         2            
Percentage of maximum voting rights       49.50% 49.50%            
Number of Investee's Board members currently representing the Company | Director         3            
Special terms on re-designating board member to board of investee       In addition, as of February 9, 2022, Armata entered into an amended and restated investor rights agreement with the Company and ISO, pursuant to which for as long as the Company and ISO hold at least 12.5% of the outstanding shares of Armata’s common stock on a fully-diluted, the Company and ISO shall have the right to designate two directors to Armata’s board of directors, and for so long as the Company and ISO hold at least 8%, but less than 12.5%, of the outstanding shares of Armata’s common stock on a fully-diluted basis, the Company and ISO shall have the right to designate one director to Armata’s board of directors, subject to certain conditions and qualifications set forth in the amended and restated investor rights agreement.              
July 2023 Credit and Security Agreement                      
Equity Investment                      
Term loan facility in aggregate amount   $ 25.0                  
Debt Instrument, annual interest rate   14.00%                  
Debt instrument maturity date   Jan. 10, 2025                  
March 2024 Credit and Security Agreement                      
Equity Investment                      
Term loan facility in aggregate amount $ 35.0                    
Debt Instrument, annual interest rate 14.00%                    
Debt instrument maturity date Jun. 04, 2025                    
Secured Convertible Credit Agreement                      
Equity Investment                      
Debt instrument, description     On January 10, 2023, we entered into a Secured Convertible Credit Agreement (the “Credit Agreement”) with Armata, under which we extended a one-year convertible note (the “Armata Convertible Note”) in an aggregate amount of $30.0 million at an interest rate of 8.0% per annum.                
Debt instrument, term     1 year                
Term loan facility in aggregate amount     $ 30.0                
Debt Instrument, annual interest rate     8.00%                
Consolidated Investees                      
Equity Investment                      
Equity method investment ownership percentage         69.40%           69.40%
Two Directors                      
Equity Investment                      
Armata outstanding shares percentage       12.50%              
Common stock and warrants                      
Equity Investment                      
Amount of securities purchase agreement                 $ 25.0    
Unrealized gain         $ 35.3 $ 15.8          
Warrants purchased in 2020                      
Equity Investment                      
Number of warrants purchased under the securities purchase agreement | shares                 8,710,800    
Exercise price of warrants | $ / shares                   $ 2.87  
Term of warrants                   5 years  
Warrants purchased in 2021                      
Equity Investment                      
Exercise price of warrants | $ / shares                   $ 3.25  
Term of warrants                   5 years  
Warrants purchased in 2022                      
Equity Investment                      
Exercise price of warrants | $ / shares                   $ 5  
Term of warrants                   5 years  
Warrants                      
Equity Investment                      
Equity and long-term investments at fair value         47.1           $ 35.3
Common stock                      
Equity Investment                      
Number of shares to be purchased under the securities purchase agreement | shares                 8,710,800    
Equity and long-term investments at fair value         104.8           81.2
Armata Convertible Note                      
Equity Investment                      
Equity and long-term investments at fair value         64.3           51.9
Unrealized gain         12.4 $ 2.8          
Armata July 2023 Term Loan                      
Equity Investment                      
Equity and long-term investments at fair value         27.4           $ 27.0
Unrealized gain         0.4            
Armata March 2024 Term Loan                      
Equity Investment                      
Equity and long-term investments at fair value         35.5            
Unrealized gain         $ 0.5            
Minimum [Member] | One Director                      
Equity Investment                      
Armata outstanding shares percentage       8.00%              
Maximum [Member] | One Director                      
Equity Investment                      
Armata outstanding shares percentage       12.50%              
Innoviva Strategic Opportunities, LLC | Common stock and warrants                      
Equity Investment                      
Amount of securities purchase agreement       $ 45.0       $ 20.0      
Innoviva Strategic Opportunities, LLC | Warrants                      
Equity Investment                      
Number of warrants to be purchased under the securities purchase agreement | shares       4,500,000       6,153,847      
Exercise price of warrants | $ / shares       $ 5              
Innoviva Strategic Opportunities, LLC | Common stock                      
Equity Investment                      
Number of shares to be purchased under the securities purchase agreement | shares       9,000,000              
Number of shares to be purchased under the securities purchase agreement | shares             1,212,122        
Number of warrants to be purchased under the securities purchase agreement | shares               6,153,847      
Amount of securities purchase agreement             $ 4.0